Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential

Core One Labs Inc. (CSE:COOL | OTCQB:CLABF | Frankfurt:LD6, WKN:A3CSSU) is pleased to announce that following the receipt of very positive results during phase one pre-clinical development studies conducted by its wholly owned subsidiary Akome Biotech Ltd., and their research partners, relating to the neuroactivities of its selected bioactive-compounds.

The results obtained from Akome and its research partners at Fundación Medina in Granada, Spain, Neuro-Zone Srl, based in Bresso, Italy and the Universidad Complutense de Madrid, during Phase 1 of pre-clinical development, clearly demonstrate that many of Akome’s chosen bio-compounds have considerable potential to exert beneficial effects that could mitigate neurological deficits associated with many central nervous system disorders and mental health conditions such as Major Depressive Disorder, Stroke, Parkinson’s Disease and Alzheimer’s Disease . Furthermore, Akome’s pharmacokinetic in-vivo studies have not presented any concerns with the metabolism, distribution, and elimination of the bio-compounds, and therefore support moving forward into the next stages of drug development.

In concert with the University of Barcelona, it is anticipated that Phase 2 development will be initiated in the coming weeks and will focus on evaluating the therapeutic potential of Akome’s bio-compounds, alone and in conjunction with various psychedelic compounds, on the central nervous system, through the incorporation of live organism models. One model currently being considered as ideal for this purpose is the model of the nematode (worm) Caenorhabditis elegans.

Akome has conducted preliminary conversations with Dr Mercè Pallàs Lliberia and Dr. Christian Griñán Ferré from University of Barcelona, Barcelona, Spain who have extensive experience with the C. elegans model and have shown interest in collaborating with Akome to test its bio-compounds alone and in combination with other psychedelics.

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.

The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100% owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other 100% owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.